Thomson Reuters Report Identifies BRIC Nations as Emerging Leaders in Global Clinical Trials Landscape

May 28, 2014
Despite challenges, increasing healthcare budgets and advancing markets in BRIC nations create significant opportunities for clinical trials

PHILADELPHIA, PA - May 28, 2014 - The Intellectual Property & Science business of Thomson Reuters, the world leader in providing intelligent information to businesses and professionals, today announced the release of Overcoming Clinical Challenges in BRIC Markets, a report exploring the benefits and challenges of conducting clinical trials in the pharmaceutical markets of the BRIC nations: Brazil, Russia, India and China.

 

The recent study utilized CortellisTM Clinical Trials Intelligence, a unique platform that integrates content from multiple sources to assess the clinical trial landscape. It found that while increased regulations, evolving clinical standards, and complex pipelines have driven some sponsors out of the BRIC nations, a rise in rank for each country is expected over the next four years, indicating blossoming healthcare budgets and markets that are ripe with opportunities for development.


“Each BRIC nation faces its own challenges as an attractive market for clinical trials, but each also has its own unique landscape and reward,” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences.

 

In Brazil, the rapidly changing clinical landscape and complexity and lengthiness of approval and import processes have been cited as the biggest drawbacks. The multiple reviews required for placebo trials and the associated timelines and cost have also discouraged global sponsors. Meanwhile, Russia and India face similar challenges. Regulations in both countries are being enacted faster than foreign pharmaceutical companies can keep up. The upheaval of the healthcare system and tumultuous landscape in Russia are seen as additional barriers.

 

China is the only BRIC country that has experienced an increase in the number of clinical trials initiated each year. Nevertheless, foreign sponsors continue to face challenges that limit their cost savings in the drug development process.

 

Despite these issues, the benefits of performing clinical trials in BRIC countries are numerous. A pool of almost three billion patients in research-rich centers across major cities leads to fast recruitment and cost-effective trials. Additionally, increased spending on healthcare and R&D fostered a growing number of educated and trained health professionals as well as investigational-medicine product manufacturers and central laboratories.

 

“Industry leaders need to be fully informed of market trends and insights when making strategic decisions,” Brett-Harris said. “This comprehensive report provides a greater understanding of the global landscape, particularly in nations that continue to emerge as players in the field.”

 

Learn more about Cortellis Clinical Trials Intelligence.

 

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. For more information, go to www.thomsonreuters.com.

 

 

 

CONTACT

 

Jen Breen

Jennifer.breen@thomsonreuters.com

215-823-1791

 

Molly Malone

molly.malone@thomsonreuters.com

215-823-3702